Great West Life Assurance Co. Can trimmed its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 91,382 shares of the company’s stock after selling 1,378 shares during the period. Great West Life Assurance Co. Can owned about 0.13% of Myriad Genetics worth $3,414,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in MYGN. Royal Bank of Canada raised its stake in shares of Myriad Genetics by 59.5% during the first quarter. Royal Bank of Canada now owns 4,597 shares of the company’s stock valued at $136,000 after purchasing an additional 1,715 shares during the period. Robecosam AG raised its stake in shares of Myriad Genetics by 39.8% during the second quarter. Robecosam AG now owns 4,193 shares of the company’s stock valued at $156,000 after purchasing an additional 1,193 shares during the period. Asset Management One Co. Ltd. purchased a new stake in shares of Myriad Genetics during the first quarter valued at approximately $176,000. Victory Capital Management Inc. purchased a new stake in shares of Myriad Genetics during the first quarter valued at approximately $185,000. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of Myriad Genetics during the second quarter valued at approximately $205,000.
Shares of NASDAQ:MYGN traded down $0.76 during midday trading on Friday, reaching $44.09. The company had a trading volume of 674,744 shares, compared to its average volume of 731,087. The company has a current ratio of 3.19, a quick ratio of 2.86 and a debt-to-equity ratio of 0.01. The firm has a market cap of $3.26 billion, a PE ratio of 36.74, a price-to-earnings-growth ratio of 3.12 and a beta of 0.51. Myriad Genetics, Inc. has a one year low of $27.23 and a one year high of $50.44.
Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, August 21st. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.05. The business had revenue of $200.90 million during the quarter, compared to analyst estimates of $195.93 million. Myriad Genetics had a net margin of 17.69% and a return on equity of 9.78%. The business’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.30 earnings per share. As a group, equities research analysts forecast that Myriad Genetics, Inc. will post 1.44 EPS for the current fiscal year.
In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the business’s stock in a transaction on Wednesday, July 11th. The shares were sold at an average price of $42.06, for a total transaction of $1,261,800.00. Following the completion of the sale, the director now owns 59,743 shares in the company, valued at $2,512,790.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Richard M. Marsh sold 70,672 shares of the business’s stock in a transaction on Wednesday, July 11th. The shares were sold at an average price of $42.88, for a total transaction of $3,030,415.36. Following the sale, the vice president now owns 154,869 shares of the company’s stock, valued at approximately $6,640,782.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 180,672 shares of company stock valued at $7,572,215. Insiders own 6.70% of the company’s stock.
A number of analysts have recently issued reports on MYGN shares. Barclays lowered shares of Myriad Genetics from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $38.00 to $30.00 in a research note on Wednesday, September 5th. Morgan Stanley upgraded shares of Myriad Genetics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $35.00 to $55.00 in a research note on Wednesday, July 11th. Zacks Investment Research lowered shares of Myriad Genetics from a “buy” rating to a “sell” rating in a research note on Monday, August 27th. Bank of America lifted their price objective on shares of Myriad Genetics from $20.00 to $31.00 and gave the company an “underperform” rating in a research note on Monday, July 16th. Finally, BidaskClub lowered shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 21st. Four analysts have rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Myriad Genetics currently has an average rating of “Hold” and an average target price of $39.10.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Recommended Story: Average Daily Trade Volume – ADTV
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.